| Announcement | Date |
|---|---|
EMBEDA® discontinuationAs of November 15, 2019, Pfizer discontinued sale of all EMBEDA® extended-release capsules. This decision was not made because of any safety or efficacy issues, or because of manufacturing concerns. Patients should talk to their healthcare provider about other appropriate treatment options. |
March 31, 2020 |
Pfizer Shares Safety Data on Azithromycin-Hydroxychloroquine CombinationOn March 25, 2020 Pfizer Inc. followed up on the recently made commitment to share data and knowledge as part of our five-point plan to battle the COVID-19 pandemic. |
March 30, 2020 |
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine |
March 24, 2020 |
US FDA Approves sNDA for Expanded Indication of Eucrisa in Children as Young as 3 Months of Age with Mild to Moderate Atopic DermatitisUS FDA Approves sNDA for Expanded Indication of Eucrisa in Children as Young as 3 Months of Age with Mild to Moderate Atopic Dermatitis |
March 24, 2020 |
Pfizer Outlines Five-Point Plan to Battle COVID-19On Friday, March 13, 2020, Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19. |
March 16, 2020 |
Tikosyn Drug Shortage Communication – Supply Status |
December 4, 2019 |
Partner4Better (P4B) Launches!Pfizer Medical Information is pleased to announce the launch of the Partner4Better (P4B) global microsite where healthcare professionals (HCPs) have access to 5 educational modules- Medical Information, Counterfeits, Health Literacy, Medication Adherence and Literature Searching. Click here to access: https://www.partner4better.com/. |
October 10, 2019 |
VYNDAQEL® OR VYNDAMAX™ Dose Conversion ToolThis tool was designed to help with VYNDAQEL® OR VYNDAMAX™ dose conversion. |
September 13, 2019 |